[Pharmacotherapy for Alzheimer's disease].

Author: VerheyF R J

Paper Details 
Original Abstract of the Article :
BACKGROUND: So far no causal therapies are available for the treatment of Alzheimer's disease. However, four drugs, namely donepezil, rivastigmine, galantamine and memantine, have been licensed for treating the symptoms of the disease. AIM: To systematically review the efficacy and side-effects of ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/16955982

データ提供:米国国立医学図書館(NLM)

Pharmacotherapy for Alzheimer's Disease: A Review of Current Medications

Alzheimer’s disease, a debilitating neurodegenerative disorder, continues to pose a significant challenge to healthcare professionals. This study delves into the current state of pharmacotherapy for Alzheimer’s disease, systematically reviewing the efficacy and side effects of available medications.

Limited but Promising Effects of Anti-Alzheimer Drugs

The researchers evaluated the efficacy of four licensed drugs – donepezil, rivastigmine, galantamine, and memantine – in managing the symptoms of Alzheimer’s disease. While these medications have been shown to have a beneficial effect on cognition and daily functioning, the effects are limited, and cholinesterase inhibitors are often associated with side effects.

The Importance of a Comprehensive Approach to Alzheimer’s Care

The study emphasizes the need for a holistic approach to Alzheimer’s care, integrating medication with psychosocial intervention techniques. The researchers recommend a careful and realistic approach to treatment, acknowledging the limitations of current pharmacotherapy. Treating Alzheimer’s disease is like navigating a vast, shifting desert landscape – it requires careful planning, adaptability, and the use of multiple tools to navigate the challenges.

Dr.Camel's Conclusion

This review provides a comprehensive overview of the current pharmacotherapeutic landscape for Alzheimer’s disease. While the available medications offer limited but promising benefits, the study highlights the need for ongoing research and development of novel therapies. It also emphasizes the importance of a multifaceted approach to Alzheimer’s care, integrating pharmacotherapy with psychosocial interventions.

Date :
  1. Date Completed 2006-09-27
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

16955982

DOI: Digital Object Identifier

16955982

Related Literature

SNS
PICO Info
in preparation
Languages

Dutch

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.